PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective

HaiXia Li¹, Chao Zheng¹, Jinming Han²,³, Jie Zhu⁴,⁵, Shan Liu¹ and Tao Jin*¹

¹ Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China, ² Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden, ³ Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China, ⁴ Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden

*Correspondence: Tao Jin
jin_tao@jlu.edu.cn

INTRODUCTION

Multiple sclerosis (MS) is an autoimmune disease characterized by demyelination, axonal injury, and neuronal loss in the central nervous system (CNS), causing a variety of clinical symptoms involving motor, sensory, visual, and autonomic systems (Dobson and Giovannoni, 2019). As a leading non-traumatic disabling disease among young adults, MS affects more than 2 million people worldwide and causes considerable social and economic burdens (Thompson et al., 2018). Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model of MS (Glatigny and Bettelli, 2018). Accumulating evidence indicates that MS and EAE are mediated by activated T cells, B cells, and innate immune cells (Cheng et al., 2017; Yang et al., 2019). However, the pathogenesis of MS is complex and more efforts are needed to elucidate the mechanisms underlying this process.

The inhibitory receptor programmed cell death protein-1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1) axis is a widely studied immune checkpoint that modulates signaling pathways related to T cell activation. The use of PD-1/PD-L1 inhibitors is a promising immune therapy strategy for cancer patients. However, individuals treated with PD-1/PD-L1 inhibitors may develop immune-related adverse events due to excessive immune reactions. Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system. T cells and the PD-1/PD-L1 axis play vital roles in the pathogenesis of MS. A better understanding of the complex relationship between the PD-1/PD-L1 axis and T cells may extend our knowledge of the molecular mechanisms and therapeutic approaches for MS. In this review, we summarize the most recent findings regarding the role of the PD-1/PD-L1 axis in MS and discuss the potential therapeutic strategies to modulate the expression of PD-1/PD-L1 in MS.

Keywords: experimental autoimmune encephalomyelitis, multiple sclerosis, T cells, programmed cell death ligand-1, programmed cell death protein-1
including systemic lupus erythematosus (SLE) (Prokunina et al., 2002), rheumatoid arthritis (RA) (Kong et al., 2005), type 1 diabetes (T1D) (Wang et al., 2005), autoimmune hepatitis (AIH) (Curran and Sharon, 2017), and MS (Kroner et al., 2005). In this article, we mainly focus on the involvement of the PD-1/PD-L1 axis in MS/EAE. Novel insights into the modification of the PD-1/PD-L1 axis as a therapeutic strategy for MS have been highlighted.

OVERVIEW OF PD-1/PD-L1

PD-1 and PD-L1 play an essential role in maintaining immune homeostasis (Keir et al., 2006). Ishida et al. (1992) first discovered that the immune checkpoint gene PD-1 was significantly upregulated during the generation of murine T cell hybridoma. The activation of the PD-1 gene is involved in programmed cell death and can promote the evasion of tumor cells from effective immune responses. By contrast, checkpoint inhibitors restore the anti-cancer activity of T cells (Ishida et al., 1992). PD-1 is a member of the B7-CD28 superfamily of type I transmembrane protein receptors with 288 amino acids, encoded by the PDCD1 gene and is located on chromosome 2q37.3. It is mainly expressed on the surface of activated T cells, B cells, dendritic cells (DC), monocytes, and natural killer cells (Chen, 2004; Okazaki and Honjo, 2006; Keir et al., 2008; Xia et al., 2016). PD-L1 (also known as B7-H1) and PD-L2 (also known as B7-DC) are two ligands of PD-1, both located on chromosome 9p21.4 and are encoded by CD274 and PDCD1LG2, respectively (Xia et al., 2016). PD-L1 is mainly expressed on activated T cells, B cells, DCs, macrophages, mesenchymal stem cells, and cultured bone marrow-derived mast cells, whereas PD-L2 is mainly expressed on DCs, macrophages, and cultured bone marrow-derived mast cells (Augello et al., 2005; Nakae et al., 2006). The expression of PD-1 and its binding affinity to ligands regulate the threshold of T cell tolerance induction and maintenance, as well as immune cell activation and cytokine secretion (Sharpe et al., 2007). The PD-1/PD-L1 axis regulates immune tolerance and its dysfunction leads to a variety of autoimmune diseases (Zamani et al., 2016).

ROLE OF PD-1 IN T CELLS

The cytoplasmic tail of PD-1 contains two tyrosine motifs: an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) (Okazaki et al., 2001). Upon PD-L1 engagement, ITIM and ITSM are phosphorylated and induce the recruitment of phosphatase Src homology-2 domain-containing protein tyrosine phosphatase (SHP2) in T cells (Okazaki et al., 2001; Sheppard et al., 2004). Subsequently, phosphorylated ITIM and ITSM reduce the phosphorylation of CD3ζ, Zap70, and protein kinase C (PKC)-ζ, downregulate the phospha-tidylinositol-3-kinase (PI3K) and serine/threonine-protein kinase (AKT) signaling pathway, and inhibit T cell proliferation and cytokine production (Sheppard et al., 2004; Hofmeyer et al., 2011). Moreover, PD-1 recruits SHP2 through the ITSM to block CD28-mediated activation of the PI3K/AKT/mTOR signaling (Parry et al., 2005). The inactivation of AKT blocks cell cycle progression by activating pro-apoptotic factors, such as Bad and procaspase-9. It also inhibits protein synthesis and glycogen metabolism by regulating mTOR, glycogen synthase kinase 3, insulin receptor substrate 1, cyclin-dependent kinase inhibitors p21CIP1/WAF1 and p27KIP1, and RAF-1 to block cell cycle progression and cell growth (Porta et al., 2014). PD-1/PD-L1 have also been shown to increase the expression of phosphatase and tensin homolog (PTEN) (Francisco et al., 2009). PTEN dephosphorylates phosphatidylinositol (3,4,5)-triphosphate (PIP3) on the cell membrane and generates phosphatidylinositol 4,5-bisphosphate (PIP2), antagonizing both the PI3K/AKT and mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) signaling pathways, thereby mediating cellular metabolism, proliferation, and survival (Weng et al., 2001; Francisco et al., 2009; Laplante and Sabatini, 2012; Figure 1).

REGULATION OF T CELLS FUNCTION

PD-1 is located adjacent to the Golgi compartments in T cells and its expression is tightly regulated (Pentcheva-Hoang et al., 2007). The level of PD-1 in naïve T lymphocytes is low or even undetectable. However, the expression of PD-1 can be rapidly induced when the T cell receptor (TCR, located on T cells) is activated. TCR activation transduces extracellular signals into cellular responses and activates specific downstream signaling, such as MAPK, PKC, calcium, etc., which ultimately causes T cell proliferation, activation, and differentiation (Pentcheva-Hoang et al., 2007; Garcia et al., 2009; Smith-Garvin et al., 2009). PD-1/PD-L1 deliver co-suppressive signals to TCR, subsequently decreasing the activation of autoreactive T cells (Bennett et al., 2003; Brown et al., 2003). The co-stimulatory molecule CD28 expressed on the surface of T cells binds to the B7 on antigen-presenting cells (APC), mediating T cell costimulation and promoting proinflammatory cytokine production (Esensten et al., 2016). PD-1 blocks the activation of the above signals when bound to PD-L1, thereby limiting inflammatory responses associated with peripheral T cell activity (Ansari et al., 2003; Keir et al., 2006; Figure 2). In addition, PD-1/PD-L1-deficient mice exhibited a low threshold of TCR stimulation to activate T cells and were prone to inflammation, such as lupus-like proliferative arthritis and glomerulonephritis (Nishimura et al., 1999; Freeman et al., 2000).

Previous studies have shown that the transcription efficiency of TCR-dependent genes is related to their sensitivity to PD-1-mediated downregulation. The genes that encode survival and proliferation-related proteins (i.e., Nfatc1, Nrf1, Egr1, Nr4a1, Cdc41b, Erbb3, etc.) are not sensitive to PD-1, and are therefore highly expressed after TCR activation. By contrast, the genes encoding cytokines and effector molecules (i.e., Ifng, Il3, Il4, Tnf, Egr2, etc.) are PD-1-sensitive genes and can therefore be effectively inhibited by PD-1 (Shimizu et al., 2020). These findings indicate that the main role of PD-1 in activating T cells is to inhibit the secretion of cytokines and effector molecules.
**PD-1/PD-L1 in MS/EAE**

Ortler et al. demonstrated for the first time that B7-H1 was highly expressed in the inflammatory areas of white matter in MS patients and was likely to be expressed on activated microglia/macrophages, which was consistent with the hypothesis that B7-H1 expression may reduce T cell activation and promote immune homeostasis in the CNS (Ortler et al., 2008). The polymorphism of the PD-1 gene is considered a modifier of MS progression. In MS, PD-1-mediated inhibition of interferon (IFN)-γ by T cells can be damaged in patients carrying PD-1 gene polymorphism (Kroner et al., 2005). The number of PD-1+CD4+ T cells, PD-1+CD8+ T cells, PD-L1+ interleukin (IL)-10+CD14+ cells, and PD-L1+IL-10+CD19+ cells in MS patients are significantly increased during the remitting phase compared with the relapsing phase, indicating that PD-1/PD-L1 also plays an immunosuppressive role in MS. The inhibition of PD-1 in lymphocytes in the acute phase of MS significantly increases the proliferation of CD4+ T cells and CD8+ T cells. However, no such effect is observed when the expression of PD-L1 is blocked in APC, indicating that PD-1 is more dominant than PD-L1 in promoting lymphocyte apoptosis and inhibiting proliferation in MS (Trabattoni et al., 2009). In addition, the expression of PD-1/PD-L1, but not PD-L2, on peripheral blood mononuclear cells (PBMC) was significantly downregulated in patients with MS compared with healthy controls (Javan et al., 2016). Although the regulatory mechanisms of the PD-1/PD-L1 axis during MS onset and progression remain unclear, it has been gradually established that the PD-1/PD-L1 axis is a classical immune suppressor in MS (Javan et al., 2016). PD-1/PD-L1 is highly expressed on activated immune cells. The expression of PD-1/PD-L1 in different immune cells in MS requires further investigation with a large sample size.

The PD-1/PD-L1 signaling also regulates the pathogenesis of EAE. The blockade of PD-1 in EAE resulted in the activation of antigen-specific T cells and the production of proinflammatory cytokines (Salama et al., 2003). The overexpression of PD-L1 in APC inhibited immune responses of autoreactive T cells in EAE, while PD-L1-deficient EAE mice showed worse clinical symptoms, evidenced by significantly upregulated IFN-γ, tumor necrosis factor (TNF)-α, and IL-17 (Salama et al., 2003; Zhu et al., 2006; Carter et al., 2007). The release of these inflammatory factors causes severe inflammatory responses, which is considered a critical step in the pathogenesis of MS and EAE (Wagner et al., 2020). The EAE mice exhibited a milder disease severity after treatment with PD-L1 fusion protein for five consecutive days. The therapeutic effects can be attributed to the suppression of Th17 cell development and the inhibition of retinoic acid-related orphan receptor (ROR)-yt and interferon regulatory factor 4 (Herold et al., 2015). Taken together, PD-1/PD-L1 regulates immunosuppressive responses. A better understanding of the regulatory mechanisms of the PD-1/PD-L1 axis...
Li et al. Targeting PD-1 for MS

FIGURE 2 | The protective effect of PD-1/PD-L1 on immune inflammatory tissues through T cells. The antigen (Ag) invades the body to activate APC. It is captured by major histocompatibility complex (MHC) molecules on APC, which binds to TCR on T cells to activate T cells. Activated T cells release pro-inflammatory cytokines, causing tissue damage. In parallel, activated APC and T cells express PD-L1 and PD-1, respectively, and the interaction of PD-L1 and PD-1 promotes the release of anti-inflammatory cytokines by T cells. The binding of PD-L1 to PD-1 also inhibits the activation of APC and T cells, thereby reducing tissue inflammation, promoting tissue repair, and protecting normal tissues from immune inflammatory response-induced damage.

axis in different immune cells may provide valuable information for the identification of novel therapeutic targets for MS/EAE.

INHIBITION OF T CELL PROLIFERATION

Lymphocyte proliferation is an early pathogenic step in MS and the inhibition of proinflammatory lymphocyte proliferation represents a therapeutic strategy for MS (Klotz and Eschborn, 2019). PD-1 inhibits the proliferation of T cells by arresting them in the G0/G1 phase (Gonzalez et al., 2005). The blockade of PD-1, however, promotes the proliferation of lymphocytes via upregulating p-AKT during the acute phase of relapsing-remitting multiple sclerosis (RRMS) (Trabattoni et al., 2009). The addition of PD-L1-Ig into T cells significantly inhibited its proliferation in vitro by increasing the proportion of cells in the G1 phase, and this effect was reversed when PD-L1 was inhibited (Zhao et al., 2015). Tasuku and colleagues proposed that cell proliferation-related genes are not sensitive to PD-1, and are therefore highly expressed after TCR activation (Shimizu et al., 2020). In the same study, PD-1−/− T cells did not exhibit a hyperproliferative phenotype in response to the stimuli via TCR. Notably, the above effects could be reversed when PD-1 binds to PD-L1, and the efficiency of immunological inhibition depends on the strength of the signal transmitted by TCR and CD28. The inhibitory effect of PD-L1 is significantly enhanced by the blockade of CD28, with TCR-mediated proliferation being reduced to 80% (Freeman et al., 2000). The underlying mechanisms are that the proliferative response is suppressed by the recruitment of Src homology 2 (SH2) domain-containing protein tyrosine phosphatase to transmit negative signals and the inhibition of tyrosine phosphorylation (Freeman et al., 2000). The rat sarcoma (Ras) plays a key role in cell proliferation, differentiation, and survival (Malumbres and Barbacid, 2003; Bertoli et al., 2019), and rapidly accelerates the progression of rat fibrosarcoma (a serine/threonine kinase serving as a downstream mediator of the Ras) (Malumbres and Barbacid, 2003)/MAPK/ERK signaling pathways by promoting cell proliferation and preventing apoptosis (Robbs et al., 2013). Patsoukis et al. (2012a) found that PD-1 selectively inhibited MAPK/ERK activation by inhibiting Ras and subsequent T cell proliferation. PD-1 arrests T cells in the G1 phase by inhibiting the transcription of SKP2, a gene that encodes a component of ubiquitin ligase (Patsoukis et al., 2012a). PD-1
In Waldenstrom macroglobulinemia, the expression of PD-L1 secretion through the PD-1/PD-L1 axis (Hirahara et al., 2012). Naïve T cells, and suppresses Th17 cell differentiation and IL-17 (Liu et al., 2015; Bommarito et al., 2017). IL-27 is an inducer of soluble PD-1 (sPD-1) in CD4+ T cells (Freeman et al., 2000). By contrast, PD-1 is decreased by 80% and the secretion of IL-2 is also reduced (Carter et al., 2003). It has been shown that PD-L1+ mice produce more cytokines, such as IFN-γ, IL-17, and TNF-α (Carter et al., 2003). In the presence of PD-L1, the secretion of IFN-γ by T cells is decreased by 80% and the secretion of IL-2 is also reduced (Freeman et al., 2000). By contrast, PD-1High T cells reduce the production of proinflammatory cytokines and increase the expression of anti-inflammatory cytokine IL-10 by upregulating a variety of inhibitory receptors, including T cell immunoglobulin and mucin domain 3, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and exhaustion-related transcription factors (e.g., Eomes and Blimp-1) (Ma et al., 2019).

Cytokines are the central component of the PD-1/PD-L1 axis. PD-1 upregulation induced by TCR activation can be significantly inhibited by the blockade of tumor growth factor beta (TGF-β) (Rekik et al., 2015). Furthermore, IFN-γ, TNF-α, IL-6, and IL-17 are inducers of soluble PD-1 (sPD-1) in CD4+ T cells (Liu et al., 2015; Bommarito et al., 2017). IL-27 is an anti-inflammatory cytokine that upregulates PD-L1 expression in naïve T cells, and suppresses Th17 cell differentiation and IL-17 secretion through the PD-1/PD-L1 axis (Hirahara et al., 2012). In Waldenstrom macroglobulinemia, the expression of PD-L1 and PD-L2 in T cells was significantly upregulated by IL-21, IFN-γ, and IL-6. IL-21 and IL-6 also induced the secretion of soluble PD-L1 (sPD-L1) in vitro (Jalali et al., 2018). IL-12 and IL-6 upregulate the expression of PD-1 following TCR activation by modulating the chromatin structure of the PD-1 (PDCD1) gene and promoting PDCD1 transcription via activation of signal transducer and activator of transcription (STAT)3/STAT4 signaling. However, IL-6 or IL-12 alone fails to exert the above effects (Austin et al., 2014). Notably, the inflammatory microenvironment is likely to impair PD-1/PD-L1-mediated T cell immune suppression. Rheumatoid arthritis and psoriatic arthritis (PsA)-associated inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, have been shown to counteract the suppressive effects of PD-1 on CD4+ T cells in vitro (Bommarito et al., 2017). Leonard and Lin demonstrated that IL-2, IL-7, and IL-15 bound to their receptors and activated STAT5 phosphorylation (Leonard and Lin, 2000). The activation of STAT5 diminished the PD-1-mediated inhibitory effect (Bennett et al., 2003).

Overall, proinflammatory cytokines promote the upregulation of PD-1/PD-L1 and exert PD-1-mediated suppressive effects. Upregulated expressions of PD-1 and PD-L1, in turn, inhibit the production of proinflammatory cytokines and promote the expressions of anti-inflammatory cytokines. A negative feedback between PD-1/PD-L1 and cytokines may exist, which may explain the role of PD-1/PD-L1 as a negative regulator of immune responses.

The expressions of PD-1 and PD-L1 are significantly increased in the brain tissues of MS patients (Ortler et al., 2008), but are downregulated after treatment (Trabattoni et al., 2009). We propose that the activation of a variety of immune cells induces the production of proinflammatory cytokines during the relapsing phase of MS, and then promotes the expression of PD-1/PD-L1. The downregulation of PD-1/PD-L1 after treatment is likely due to significantly reduced proinflammatory cytokines. The effects of secreted inflammatory cytokines on the expression and function of PD-1/PD-L1 in MS remain to be elucidated.

**REGULATION OF T CELL DIFFERENTIATION**

**Th1 and Th2 Cells**

Th1 cells are a principle subset of effector CD4+ T cells that secrete inflammatory cytokines (e.g., IFN-γ, TNF-α, and IL-2) and play a pathogenic role in MS (Olsson, 1995; Sospedra and Martin, 2005). Th2 cells secrete IL-13, IL-4, IL-5, IL-10, and TGF-β to maintain immunological tolerance. A balance between Th1 and Th2 cells is important for human health (Yeh and Lin, 2020). The imbalance between Th1 cell- and Th2 cell-secreted cytokines is a key driver in the pathogenesis of MS (Sospedra and Martin, 2005; Hirahara and Nakayama, 2016). PD-L1 modulates CD4+ T cell differentiation by reducing the numbers of IFN-γ+CD4+ Th1 and IL-17+CD4+ Th17 cells (Figure 3), while increasing the proportions of IL-4+CD4+ Th2 and CD4+Foxp3+ regulatory T’ (Treg) cells (Ding et al., 2016). In prostate and advanced melanoma cancer, the blockade of PD-1 significantly enhances Th1 effector response by augmenting the secretion of IFN-γ and
IL-2, but inhibits Th2 by blocking the production of IL-5 and IL-13 (Dulos et al., 2012; Figure 3). One explanation is that PD-1 inhibition activates the PI3K/AKT and cellular metabolic pathways, promoting the secretion of IFN-γ and IL-2 from T cells. However, another study showed that the blockade of PD-1 had no effect on cytokine secretion by Th2 cells (Li et al., 2015). These inconsistent results may be explained by the Th2-driving conditions in different tumor microenvironments. Additionally, in immune thrombocytopenic purpura, sPD-L1 improves the imbalance between Th1 and Th2 cells by activating the PD-1/PD-L1 pathway, which further inhibits the secretion of IFN-γ and promotes the production of IL-4 and TGF-β (Wu et al., 2019).

Furthermore, the suppression of the inhibitory signal cascade generated by the binding of ITIM, ITSM, and SHP-1/2 to the PD-1 cytoplasmic tail triggers chromatin changes in the promoter regions of the IL-2 and IFN-γ genes and upregulates their transcription (Riley, 2009). In head and neck squamous cell carcinoma, PD-L1 binds to PD-1 to activate the downstream SHP-2, resulting in the inhibition of p-STAT1, T-bet, and p-S6, and the subsequent downregulation of Th1 cytokines, including IFN-γ, TNF-α, and IL-2. However, the secretion of IL-10 from Th2 cells was not affected (Li et al., 2015). The activation of SHP-2 can also bypass the PD-1 signaling to inhibit p-STAT1/T-bet, thereby suppressing immune responses in Th1 cells (Li et al., 2015). Therefore, PD-1/PD-L1 or SHP-2 agonists may serve as promising therapeutic targets for MS.

Th17 and Treg Cells
Th17 cells represent a subset of CD4+ T cells secreting IL-17A, IL-17F, IL-6, IL-22, TNF-α, IL-23, and C-C chemokine receptor 6, which damage the blood-brain barrier (BBB) and enhance its permeability (Littman and Rudensky, 2010; Moser et al., 2020). Furthermore, Th17 cells induce the recruitment of neutrophils, macrophages, and monococytes to the inflamed sites in the CNS (Waisman et al., 2015). Treg cells are a subset of CD4+CD25+ T cells expressing Foxp3. They have been shown to suppress over-activated immune responses by producing anti-inflammatory cytokines, including TGF-β and IL-10 (Tang and Bluestone, 2008; Lee, 2018). Treg cells also maintain immune homeostasis by inhibiting effector CD4+ T cell subsets (Danikowski et al., 2017). Genetic abnormalities of CTLA-4 and CD25, and a low expression level of Foxp3 in Treg cells are closely related to the pathogenesis of MS (Danikowski et al., 2017; Kimura et al., 2018).

The PD-1/PD-L1 interaction plays a vital role in the differentiation, maintenance, and function of Treg cells. There are two main subsets of Treg cells, the “natural” CD4+ Treg cells that are developed in the thymus and the “induced” Treg (iTreg) cells that are developed from peripheral CD4+ T cells (Haribhai et al., 2016). Previous studies have indicated that the activation of the PI3K/AKT/mTOR signaling pathway strongly inhibits the differentiation and development of iTreg cells. However, PD-1/PD-L1 downregulates p-PI3K, p-mTOR, and p-AKT, and increases the expression of Foxp3 in iTreg cells, thereby promoting iTreg cell differentiation and maintaining their function (Figure 1; Haxhinasto et al., 2008; Francisco et al., 2009; Ding et al., 2016). In contrast, the PI3K/AKT/mTOR pathway positively affects Th17 cell differentiation (Figure 1; Kurebayashi et al., 2012; Nagai et al., 2013). The endolysosomal protease asparaginyl endopeptidase (AEP) is responsible for destabilizing Foxp3 in Treg cells. PD-1/PD-L1 maintains a high expression level of Foxp3 in Treg cells by inhibiting AEP, and therefore generates stable and functionally robust Treg cells in vivo and maintains the balance of the immune system (Statthopoulou et al., 2018). sPD-L1 and TGF-β promote the transformation of immature T cells to Treg cells. It has also been reported that the number of Treg cells in PD-L1-deficient mice was significantly decreased compared with the control group (Francisco et al., 2009). In vivo, the suppressive effect of Treg cells is reduced when PD-1 is blocked (McGrath and Najaian, 2012).

Many studies have demonstrated that the differentiation between Th17 cells and Treg cells is essential for maintaining the balance of the immune system, and the dysregulation of the system may contribute to MS pathogenesis (Kimura and Kishimoto, 2010; Jamshidian et al., 2013). PD-1/PD-L1 maintains immune homeostasis by inhibiting immune responses of Th17 cells and promoting Treg cells (Figure 3). In a study of pre-eclampsia, the imbalance was manifested by an increase in the number of Th17 cells and a decrease in Treg cells due to low expression of PD-1/PD-L1 at the maternal-fetal interface (Tian et al., 2016). Treatment with PD-L1 Fc promoted the differentiation of naive CD4+ T cells to Treg cells in vitro (Zhang et al., 2018).

Tumor growth factor beta is a key stimulating factor for the differentiation of Treg cells (Omenetti and Pizarro, 2015). In the presence of TGF-β, PD-1 inhibitors promote Th17 cell responses and prevent the development of Treg cells (Figure 3). In the presence of IL-6, IL-23, and IL-1β, treatment with PD-L1 Fc induces the differentiation of naive CD4+ T cells into Treg cells, even though the microenvironment may promote Th17 differentiation (Zhang et al., 2018; Figure 3). These findings indicate that the regulatory effects of PD-1/PD-L1 on maintaining the balance of Th17/Treg are stronger than those of inflammatory factors. The differentiation of naive CD4+ T cells into Th17 or Treg cells depends on the cellular levels of master regulatory factors, RORγt and Foxp3. When Foxp3 was dominantly expressed, naive CD4+ T cells were differentiated into Treg cells, while the excessive expression of RORγt leads to the differentiation of naive CD4+ T cells into Th17 cells (Omenetti and Pizarro, 2015). The inhibition of both PD-1 and PD-L1 blocks the PI3K/AKT/m-TOR pathway, enhances the expression of PTEN, and increases the expression of Foxp3 (Figure 1). The blockade of the PI3K pathway regulates the nuclear translocation of RORγt and IL-17, thus reducing Th17 cell differentiation (Francisco et al., 2009; Tian et al., 2016).

The signal transducer and activator of transcription 3 (STAT3) is an essential factor in Th17 cell differentiation and development. STAT3 phosphorylation restrains Treg cell development and IL-10 production (Wei et al., 2008). The aberrant activation of the STAT3 signaling causes an imbalance between Th17 and Treg cells (Wei et al., 2008). A recent study showed that the expression of PD-1 in Th17 cells was significantly upregulated in idiopathic pulmonary fibrosis, which promoted the development of Th17 cells, increased the secretion of IL-17, and therefore...
FIGURE 3 | Regulation of PD-1/PD-L1 between Th1/Th2 and Th17/Treg cells. The binding of PD-1/PD-L1 inhibits the differentiation of Th1/Th17 cells and the secretion of pro-inflammatory cytokines, thus further inhibiting the inflammatory responses. Meanwhile, the binding of PD-1/PD-L1 promotes the differentiation of Th2/Treg cells and the secretion of anti-inflammatory cytokines, thus exerting an immunosuppressive effect. In addition, the addition of PD-L1 to the microenvironment where naive T cells differentiate into Th17 cells inhibits the production of Th17, while the blockade of PD-1 to the microenvironment where naive T cells differentiate into Treg inhibits the production of Treg cells.

created a pro-fibrotic microenvironment (Celada et al., 2018). It has also been confirmed that high expression of PD-1 in Th17 cells enhances the STAT3 signaling, promoting Th17 cell development and IL-17 production (Celada et al., 2018). Both direct and indirect regulatory mechanisms may exist in PD-1-mediated Th17 cell differentiation. PD-1 expressed on Th17 cells can upregulate STAT3 and promote the differentiation and maturation of Th17 cells. In addition, the binding of PD-1 to PD-L1 indirectly decreases the number of Th17 cells by inhibiting the PI3K/AKT pathway. Previous studies mainly focused on the combined regulatory effects of PD-1/PD-L1 on cells. However, PD-1 or PD-L1 alone may also exert regulatory effects on immune cells. The regulatory mechanisms of PD-1 and PD-L1 in immune responses are far more complex than previously understood.

Paradoxical Role in Tfh Cells
Tfh cells, located at the T cell-B cell border, are a major source of extrinsic factors that promote the formation, expansion, and isotype switching of germinal centers (GCs) (Toellner et al., 1996; Allen et al., 2007). Tfh cells aid B cells and promote neuroinflammation in MS (Schmitt, 2015; Quinn and Axtell, 2018; Huber and Chang, 2020). Tfh cells also promote the infiltration of B cells into the CNS, while Tfh cell deficiency alleviates the symptoms of EAE (Bagaeva et al., 2006; Schafflick and Xu, 2020). Although the regulatory role of PD-1 in Tfh cells has not been fully elucidated, it has been suggested that PD-1/PD-L1 affects the development and function of Tfh cells (Blackburn et al., 2009; Serriari et al., 2010).

Two phenotypes of C-X-C chemokine receptor 5 (CXCR5)+ Tfh cells have been identified in both mice and humans: the effector phenotype of CCR7loPD-1hiCXCR5+ helper T cells and the resting phenotype of CCR7hiPD-1loCXCR5+ helper T cells. Once stimulated with antigen, CCR7loPD-1hiCXCR5+ Tfh cells are rapidly differentiated into mature Tfh cells to facilitate humoral immune responses. The Tfh phenotypes with high PD-1 expression are more associated with autoimmune diseases (He et al., 2013). In terms of immunosuppression, the overexpression of PD-1 in Tfh cells reduces the number of CXCR5hi or CXCR5hiBcl-6hi Tfh cells (Shi et al., 2018). In Tfh cells, PD-1 binds to PD-L1 to inhibit the activity of the PI3K signaling pathway, thereby reducing the expression of the follicle guidance receptor CXCR5 and inhibiting the recruitment of Tfh cells to follicles. In addition, PD-1 inhibits the recruitment of Tfh...
to follicles via recruiting and activating SHP2 through the ITSM motif (Y248) (Shi et al., 2018).

In terms of immune enhancement, PD-1 combines with PD-L1 in the follicular mantle, regulating the chemo-sensing program of CXCR5+CCR7loSIPR2+ Tfh cells (favor localization to the follicular center) and promoting Tfh cells to enter the GC, which is beneficial for B cell maturation and the production of antibodies. PD-1 weakens the potential of Tfh cells to escape from the follicular area by dampening the expression of CXCR3, which further enhances the accumulation of Tfh cells in GC (Shi et al., 2018). High expression of PD-1 on Tfh cells upregulates IL-4 and IL-21, and promotes the maturation of B cells in GCs and plasma cells (Good-Jacobson et al., 2010, 2012). The interaction of PD-1/PD-L1 optimizes B cell affinity maturation, which increases the number of effector cells with a high affinity, and thus prevents the proliferation of autoreactive, low-affinity cells (Good-Jacobson et al., 2010; Shi et al., 2018). High expression of PD-1 on Tfh cells can increase the survival of B cells in GC, which increases the proportion of cells entering into the long-lived B cell compartment and further promotes the generation of long-lived plasma cells (Good-Jacobson et al., 2010). The combination of PD-1 on Tfh cells and PD-L2 on B cells decreases the population of Tfh cells (Figure 3; Peng et al., 2019). PD-1 expressed by Tfh cells inhibits the differentiation of Tfh cells when combined with PD-L1 on DCs (Sage and Schildberg, 2018). One explanation for the regulation of PD-1/PD-L1 expression and Tfh cells is that high PD-1 expression reduces the number of Tfh cells; however, it also enhances the maturation of Tfh cells and the secretion of cytokines. A previous study of Fingolimod-treated MS patients has confirmed that the number of Tfh cells is reduced, but the proportions of PD-1+ Tfh cells and activated Tfh cells are increased in this population (Claes et al., 2014). The dual regulatory mechanisms between PD-1/PD-L1 and Tfh cells suggest that PD-1/PD-L1 not only plays an immunosuppressive role but also promotes immune responses. A prevailing hypothesis is that adaptive alteration of PD-1 expression may occur in a chronic inflammatory environment. High PD-1 expression on Tfh cells boosts long-lived antibody responses when the acute cytotoxic response is ineffectual, which protects against pathological damage caused by chronic inflammation (Good-Jacobson et al., 2010).

CONTROVERSIAL ROLE OF sPD-1/sPD-L1

PD-1/PD-L1 has two forms, the membrane-bound form and the soluble form. The membrane-bound PD-1/PD-L1 is the earliest and the most widely recognized and the sPD-1/sPD-L1 is mainly produced by the proteolytic cleavage of the membrane-bound form (Abu Hejleh et al., 2019). At present, the exact role of sPD-1/sPD-L1 in MS remains vague, and whether immunosuppressive signals, like PD-1/PD-L1, are transmitted is still controversial. Guillain-Barre Syndrome (GBS) occurs in response to T cell-mediated inflammatory autoimmune demyelination of peripheral nerves, leading to an array of symptoms, such as acute weakness of the extremities, hyporeflexia, and areflexia. Experimental autoimmune neuritis (EAN) is a classical animal model of GBS (Shen and Chu, 2018). Ding et al. found that treatment of EAN mice with sPD-L1 alleviated the symptoms of EAN, inhibited inflammatory cell infiltration and sciatric nerve demyelination, and delayed neurological progression of EAN (Ding et al., 2016). Mahoney and Shukla (2019) discovered an alternative splicing variant of the PD-L1 gene, which encodes the secreted form of PD-L1 (secPD-L1), consisting of 18 amino acid tail sequences that contain cysteine and can therefore be homo-dimerized (Mahoney and Shukla, 2019). The secPD-L1 is functionally active, and thus can bypass the binding to PD-1 and independently inhibit T cell proliferation and IFN-γ production stimulated by CD3/CD28 co-activation. The inhibitory effect of secPD-L1 is stronger than that of the extracellular domain of monomeric sPD-L1. They also found that the homodimers of secPD-L1 are expressed in both normal tissues and activated myeloid cells that are converted from peripheral blood cells and tumors (Mahoney and Shukla, 2019). The data on the potential role of sPD-1/sPD-L1 in MS is virtually non-existent. Notably, the injection of EAE mice with B7-H1-Ig fusion protein effectively alleviated the clinical symptoms of EAE (Herold et al., 2015). These data implies that sPD-L1 may maintain immune homeostasis in MS by negatively regulating immune responses. Nevertheless, some controversies remain. It has been reported that sPD-1 was upregulated in the inflammatory microenvironment in RA and PsA, which counteracted PD-1-mediated suppression of CD4+ T cells and increased the proliferation of effector T cells (Bommarito et al., 2017). Collectively, the sPD-1 receptor may modulate PD-1 ligation under physiological conditions, which increases the resistance of CD4+ T cells to PD-1-mediated suppression. Also, the increased secretion of sPD-1 in RA and PsA is mainly attributed to the elevated secretion of inflammatory cytokines, such as TNF-α and IL-6 (Bommarito et al., 2017). Similar to RA, sPD-1 inhibits the PD-1/PD-L1 axis and enhances the activity and proliferation of T cells in aplastic anemia which involves another splicing variant of PD-1, deltaex3. This variant lacks a transmembrane domain but has a soluble extracellular domain, which functionally blocks the regulation of the membrane-bound form of PD-1 on activated T cells, thus counteracting the inhibition effect of PD-1 on T cells (Dong et al., 2003; Wan et al., 2006; Wu et al., 2009). The level of sPD-1 is significantly increased in patients with autoimmune hepatitis (AIH) during the period of disease activity and in AIH patients who have poor response to standard treatments, which suggests that sPD-1 exerts a proinflammatory effect and can be used as a clinical biomarker to evaluate the progression of AIH (Hadley et al., 2020).

The role of sPD-1/sPD-L1 in the immune response is controversial. The soluble forms of PD-1 and PD-L1 increase the complexity and diversity of the PD-1/PD-L1 pathway. The regulatory effects of sPD-1/sPD-L1 in autoimmune diseases and tumors have been reported in previous studies (Table 1). They found that the expression of sPD-1/sPD-L1 was upregulated in patients with autoimmune diseases compared with healthy subjects, but downregulated after treatment, suggesting that sPD-1 may resist the inhibitory effect of membrane-bound PD-1 on T cells, thereby indirectly enhancing immune responses.

Frontiers in Cellular Neuroscience | www.frontiersin.org 8 July 2021 | Volume 15 | Article 716747
| Variable | Diseases (year) | Specimens | Groups | Results | The factors affecting sPD-1 or sPD-L1 expression | The regulatory effects of sPD-1 or sPD-L1 | Conclusion |
|----------|----------------|-----------|--------|---------|-----------------------------------------------|------------------------------------------|------------|
| sPD-1    | Rheumatoid arthritis (RA) (2019) (Liu et al., 2019) | Sera, synovial fluid | Osteoarthritis (OA); Healthy control (HC); The level of RA disease activity (low, moderate, high) | RA > OA RA > HC Hi-RA > Lo-RA | IFN-γ, TNF-α, IL-17A upregulated sPD-1 | sPD-1 blocked the inhibitory effect of membrane-bound PD-1 on T cell activation, and induced the Th1/Th17 immune response | sPD-1 aggravated the severity of RA |
| sPD-1    | Myasthenia gravis (MG) (2019) (Yan et al., 2019) | Plasma | Untreated-stage MG; Remission-stage MG (RSMG); HC | sPD-1; USMG > RSMG USMG > HC sPD-L1; no difference | The level of sPD-1 was positively correlated with the number of Tfh cells and IL-21, and had no correlation with the expression of PD-1 on CD4+ T cells | sPD-1 may interfere with the immunosuppressive effect of PD-1 on Tfh cells, thereby over-activating Tfh cells | The level of sPD-1 was positively correlated with the concentration of acetylcholine receptor antibody, which might promoted immune response and aggravated the progression of MG |
| sPD-1    | Autoimmune hepatitis (AH) (2017) (Aarslev et al., 2017) | Plasma | Active disease; Standard-therapy; complete responders; Incomplete-responders; HC | Active disease and incomplete-responders > responders and HC | sPD-1 was produced by the release of activated PD-1+ T cells | sPD-1 promotes the activation and development of T cells by blocking the binding of PD-L1 on monocytes and PD-1 on T cells | The level of sPD-1 can reflect the degree of T cell activation, which promotes immune response and aggravates AH |
| sPD-1    | Type 2 diabetes mellitus (T2DM) (2013) (Shi et al., 2013) | Serum | T2DM; T2DM with atherosclerotic (AS); HC | T2DM > HC T2DM with AS > T2DM | The amount of sPD-1 was positively correlated with IFN-γ | sPD-L1 enhances T cell activation, proliferation, and development by blocking PD-1/PD-L1 signaling | Elevated sPD-L1 is closely associated with the severity of diabetic atherosclerotic macrovascular disease |
| sPD-1    | Aplastic anemia (AA) (2009) (Wu et al., 2009) | Sera | AA; severe AA; Chronic AA; HC | AA > HC Severe AA > chronic AA | The over-expression of PD-1ΔEx3 (a gene polymorphism of PD-1) increased the yield of sPD-1 | sPD-1 may block the immunosuppressive function of PD-1 ligands by acting as the autoantibody of PD-1 ligands, thereby inhibiting T cell apoptosis, and enhancing T cell proliferation and T cell toxicity | sPD-1 promotes the immune response and aggravates AA |
| sPD-1    | Human immunodeficiency virus (HIV) (2019) (Zilber et al., 2019) | Plasma | Primary HIV infection; HC | HIV > HC After treatment: HIV = HC | sPD-1 was positively correlated with the expression of PD-1 on the surface of CD4+ and CD8+ T cells | sPD-1 is associated with T cell exhaustion and can reflect the degree of T cell exhaustion | sPD-1 can act as a measure biomarker of immune exhaustion in HIV |
| sPD-1    | Waldenstrom macroglobulinemia (WM) (2018) (Jalali et al., 2018) | Serum | WM; HC | WM > HC | IL-21 and IL-6 increased sPD-L1 secretion in the culture medium of WM cell lines | The proliferation of T cells is inhibited by sPD-L1 by down-regulating p-AKT, p-ERK and the cell cycle protein cyclin A. sPD-L1 also regulates the metabolic rate of T cells by reducing the maximum respiration capacity of T cells and inhibiting the production of mitochondrial adenosine triphosphate | sPD-L1 promotes disease progression in WM |
| sPD-1    | Malignant melanoma (MM) (2017) (Zhou et al., 2017) | Plasma, sera | MM: pretreatment; HC | Pretreatment > HC | IFN-γ, IFN-α, and TNF-α induced the secretion of sPD-L1 | sPD-L1 inhibits the activation and proliferation of T cell | The high pretreatment level of sPD-L1 is closely related to the poor effect of PD-1 blockade |
| sPD-1    | Diffuse large B-cell lymphoma (DLBCL) (2021) (Vajavaara and Mortensen, 2021) | Serum | Prior to treatment, After three immunochemotherapy courses, At the end of therapy | Prior to treatment > after three therapy courses and at the end of therapy | The sPD-1 level of prior to treatment was positively correlated with the number of PD-1+ T cells and translated to a lower survival | Pretreatment sPD-1 level reflects T cell exhaustion | High expression of sPD-1 decreases survival of patients. sPD-L1 is not associated with poor outcome |
(Wu et al., 2009; Shi et al., 2013; Liu et al., 2015; Aarslev et al., 2017; Yan et al., 2019). It is also likely that the upregulation of sPD-1 during severe inflammation is a self-protection mechanism of the body to combat inflammation. In vitro, sPD-L1 inhibited T cell activation, proliferation, and metabolism, thereby promoting tumor immune escape. High sPD-1 levels may be associated with the exhaustion of T cells and can be used as a prognostic marker of cancers (Zhou et al., 2017; Jalali et al., 2018). Moreover, high expression of sPD-L1 in tumors is related to the splicing variant of the PD-L1 gene, which lacks the transmembrane domain and can cause abnormal secretion of sPD-L1 (Zhou et al., 2017). The splicing variation may be related to genetic predisposition. We speculate that the polymorphism of the PD-L1 gene may also be affected by pathological microenvironment. Cytokines, chemokines, and even exosomes in the microenvironment may cause abnormal secretion of sPD-1/sPD-L1. The contradictory role of sPD-1/sPD-L1 in autoimmune diseases and tumors suggest that they may be secreted by different cells. Tumor cells are the main source of sPD-1/sPD-L1 in tumors, while in autoimmune diseases, sPD-1/sPD-L1 are mainly produced by immune cells. Therefore, there might be different subtypes of sPD-1/sPD-L1 with various functions. Proteomics, metabolomics, or transcriptomics may be used to identify the subtypes of sPD-1/sPD-L1 for targeted therapies.

The immunomodulation of sPD-1/sPD-L1 in MS has not been fully characterized. Several questions need to be addressed in future studies: (1) What are the plasma levels of sPD-1/sPD-L1 in MS patients, especially in acute and remission phases? (2) Is the immune response in antigen-specific T cells positively or negatively regulated in MS? (3) Does the immune response affect PD-1 expression in T cells and PD-L1 expression in DCs? (4) Is it possible to exert an immunosuppressive effect on T cells and DCs by regulating sPD-1/sPD-L1?

**THERAPEUTIC AGENTS TARGETING PD-1/PD-L1**

Multiple sclerosis is generally considered incurable. Current treatment strategies aim to: (1) reduce immune-inflammation in the acute phase, therefore alleviating the symptoms; (2) reduce the recurrence of MS using the “disease-modifying” therapies (DMTs). Glucocorticoids are widely recognized as the first-line treatment for MS in the acute phase. Dexamethasone has been found to upregulate the expression of PD-1 in T cells in cancer therapy (Xing et al., 2015). With the widespread use of PD-1 antibodies in tumor therapy, potential side effects have also been reported. For example, the function of the adrenal cortex may be impaired after PD-1 antibody treatment, leading to adrenocortical insufficiency and decreased cortisol secretion, suggesting a correlation between the PD-1/PD-L1 axis and glucocorticoids. Although it remains unclear whether glucocorticoid therapy affects the expression of PD-1/PD-L1 in immune cells in MS, we propose that glucocorticoid therapy may exert an immunosuppressive effect by increasing the expression of PD-1 on immune cells. Estrogen plays an immunoprotective role in EAE mice by upregulating PD-L1 on monocytes and macrophages in the peripheral blood and CNS (Seifert et al., 2019). At the same time, estrogen increases the expression of PD-L1 on DCs, which further promotes the formation of tolerant DCs and therefore alleviates the development of EAE (Pappenfuss et al., 2011). Estrogen also protects against EAE by upregulating PD-L1 on B cells (Bodhankar et al., 2011) and Treg cells (Wang et al., 2009).

The DMTs, including IFN-β, fingolimod, siponimod, teriflunomide, natalizumab, rituximab, ocrelizumab, and dimethyl fumarate, effectively reduce the recurrence in patients with MS (Bar-Or et al., 2014; Ciotti and Cross, 2018; Rae-Grant et al., 2018). Short-term IFN-β treatment has been shown to upregulate the expression of PD-L1 on monocytes in MS patients (Feng et al., 2019). IFN-β also alleviates MS by upregulating PD-L1 on semi-mature DCs and inhibiting the activation of CD4+ T cells, which maintains peripheral immune tolerance (Schreiner et al., 2004). Additionally, IFN-β treatment directly promotes the expression of PD-L1 on CD4+ T cells and exerts an immunosuppressive effect on T cells in MS patients (Wiesemann et al., 2008). Fingolimod (FTY720) is an immunomodulatory drug for the treatment of RRMS. It is the first-generation sphingosine-1-phosphate receptor (S1PR) that reduces the frequency of disease recurrence in MS patients by restraining lymphocytes in lymph nodes and preventing further damage to the CNS (Brinkmann et al., 2010; Cohen et al., 2010; Claes et al., 2014). The expression of PD-1 on Tfh cells is evidently increased after fingolimod treatment (Claes et al., 2014). Preclinical studies showed that co-culture of FTY720-treated bone marrow-derived dendritic cells and T cells promoted the proliferation of Treg cells and upregulated PD-1 expression on T cells (Heng et al., 2010). Siponimod is the second-generation S1PR that has been approved to treat secondary progressive MS (Mao-Draayer et al., 2017). Siponimod upregulates the expression of PD-1 on Treg cells and promotes the proliferation of Treg cells in MS (Wu et al., 2020).

The PLP1 mutant was first identified in MS patients with neuroinflammation, axonal degeneration, neuron loss, and brain atrophy (Warshawsky et al., 2005; Groh et al., 2016). The mutation of the PLP1 gene leads to myelin sheath and axonal damage by enhancing the immune effect of cytotoxic CD8+ T lymphocytes (Groh et al., 2016). Mice with mutant PLP1 gene showed a reduced number of CD8+ effector T cells in the CNS and increased proliferation of CD8+CD122+PD-1+ regulatory T cells after treatment with teriflunomide (Groh et al., 2018). It remains unclear whether teriflunomide affects the expression of PD-1 on CD4+ T cells or the expression of PD-L1 on APC in MS patients. Dimethyl fumarate, an immunomodulator approved for the treatment of RRMS, inactivates cytotoxic-rich proteins by succination (Blair, 2019; Saidu et al., 2019). Dimethyl fumarate inhibits aerobic glycolysis in activated myeloid and lymphocytes by succinating the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase, thereby exerting an anti-inflammatory effect and preventing recurrence (Kornberg and Bhargava, 2018). In one MS patient, PD-1 was highly expressed on CD8+ T cells and memory effect T cells after dimethyl fumarate treatment, which promoted the exhaustion of T cells, while the PD-1
level was decreased after discontinuation of dimethyl fumarate (Garcia et al., 2020).

In summary, DMT plays an immunoregulatory role via regulating the expression of PD-1/PD-L1 on different immune cells. It is worth noting that reports in this field are scarce and future studies using animal models are warranted.

**RECENT RESEARCH IN MS**

Single-nucleotide polymorphisms (SNPs) have been a focus of interest for several years. Studies have shown that SNPs in PDCD1 are associated with a number of autoimmune diseases, including SLE (Fathi et al., 2020), RA (Kong et al., 2005), T1D (Qian et al., 2018), and ankylosing spondylitis (AS) (Liu et al., 2011). To date, only two studies have reported the association between SNPs in PDCD1 and MS (Kroner et al., 2005; Pawlak-Adamska et al., 2017). One study performed genotyping analysis of PD-1 expressed on T cells from patients with different types of MS. It was found that an intronic 7146G/A polymorphism of PD-1 had no effect on MS susceptibility, but significantly promoted the progression of MS. The functional assessment of the protein encoded by the mutated PD-1 gene showed that the secretion of IFN-γ by T cells was decreased (Kroner et al., 2005). Although this study did not investigate the effect of the mutated PD-1 gene on T cell proliferation, apoptosis, or differentiation, it highlighted the potential involvement of the mutation of the PD-1 gene in the pathogenesis of MS. Another study showed that the polymorphism in PDCD1 affected the symptoms and severity of RRMS (Pawlak-Adamska et al., 2017). The authors selected three SNPs of PD-1: PD-1.3 (rs11568821, intron 4), PD-1.5 (rs2227981, exon 5), and PD-1.9 (rs2227982, exon 5). They found that the presence of the PD-1.5T allele was associated with the initial presentation of MS. For example, it mainly caused pyramidal tract symptoms but prevented diplopia. Moreover, the PD-1.3G/PD-1.5T/PD-1.9T haplotype did not lead to severe RRMS, whereas ePD-1.3G/PD-1.5T/PD-1.9C haplotype prevented diplopia (Pawlak-Adamska et al., 2017). As for the mechanism of action of PD-1.3A, Prokunina et al. (2002) showed that PD-1.3A destroyed the binding site in Runt-related transcription factor 1, reduced the mRNA expression of PD-L1, inhibited autoimmune tolerance, and induced autoimmune reactions. Regarding the mechanism of action of other SNPs in PD-1, different haplotypes may lead to different clinical symptoms or types of MS, which require further investigation. Previous literature described that the genotype frequency of the PD-1.3 site varied greatly among different ethnic groups (Prokunina et al., 2002). Therefore, independent analysis in a targeted manner is needed to identify the relationship between SNPs in PD-1 and MS. Ethnic and regional differences should also be taken into account.

MicroRNAs (miRNAs) are small endogenous non-coding RNA molecules composed of approximately 21–25 nucleotides (Kim et al., 2017). They usually target one or more mRNAs for degradation or regulate the translation of targeted mRNAs (Chavali et al., 2011). Nearly 30% of protein-coding gene expression is controlled by miRNAs (Kim et al., 2017). They play a diverse role in regulating cell growth, development, proliferation, differentiation, maturation, and apoptosis (Roccaro et al., 2009), and mediate many physiological and pathological processes at the posttranscriptional level (Ferrajoli et al., 2013). Recent studies have demonstrated that miRNA is involved in the pathogenesis of MS and can be used as a biomarker for the diagnosis and prognosis of MS, as well as for monitoring disease activity (Piket et al., 2019; Mansoor et al., 2020). More than 500 miRNAs are dysregulated in immune cells, cerebrospinal fluid, and serum samples from MS patients (Mansoor et al., 2020). Small-molecule inhibitors for specific miRNAs or antisense oligonucleotides may be used to treat MS in the future (Tufekci et al., 2010; Zare-Shahabadi et al., 2013).

In MS patients who failed to respond to first-line therapy, the expression of miR-155, a proinflammatory miRNA, is significantly upregulated on T cells (Arruda et al., 2015). MiR-155 deletion in EAE mice suppressed the secretion of IFN-γ and IL-17, inhibited the development of Th17 cells, and reduced oxidative stress response and BBB permeability (Juźwik et al., 2019). MiR-16 and miR-142-3p also play a proinflammatory role in MS via regulating T cell activation. Their overexpression is related to T cell-mediated autoimmune inflammation (Arruda et al., 2015). It was found that miR-16, miR-155, and miR-142-3p on T cells were significantly upregulated in MS patients who failed to respond to first-line therapy, while the expressions of FoxP3, FoxO1, PDCD1, and IRF2BP2 were notably decreased. After autologous hematopoietic stem cell transplant (AH SCT), the expressions of miR-16, miR-155, and miR-142-3p were decreased, while the levels of FoxP3, FoxO1, PDCD1, and IRF2BP2 were significantly elevated. The upregulation of PDCD1 after AH SCT may be due to the downregulation of miR-16, since PDCD1 is a target gene of miR-16 (Arruda et al., 2015). We speculate that miR-155 may also be involved in PDCD1 expression. MiR-155−/− mice were highly resistant to EAE, while PD-1 deletion restored their susceptibility to EAE (Zhang and Braun, 2014). The mechanism may be related to the antagonistic regulation of miR-155 and PD-1 on suppressor of cytokine signaling 1 (SOCS1) and its downstream STAT1/3 pathway, which stimulates the production of IFN-γ and IL-17 (Zhang and Braun, 2014). Another study showed that miR-155 depletion inhibited the activation of T cells, but this effect could be reversed by blocking PD-1 in tumors (Huffaker et al., 2017). The PD-1 antibody therapy increases the expression of miR-155 on T cells in tumors (Martinez-Usatorre et al., 2019). The Bortezomib therapy increased the expression of miR-155 in T cells, thereby downregulating the levels of its targets, SOCS1 and SH2-containing inositol 5′-polyphosphates 1 (SHIP1), and significantly decreasing the number of SHIP1−PD-1+ T cells (Renrick et al., 2021). Furthermore, miR-155 suppressed tumor progression by inhibiting the expression of PD-L1 in tumors (Yee et al., 2017).

The recurrence rate of pregnant MS patients is 66% less than that of other MS patients. One study showed that the expressions of miR-1, miR-20a, miR-28, miR-95, miR-146a, miR-335, and miR-625 in the PBMC of pregnant MS patients were downregulated, while the levels of IL10, PD1L, and PD2L were increased compared with untreated MS patients. They concluded that IL10, PD1L, and PD2L were the targets of these miRNAs and there was a negative correlation between them.
the PD-1 pathway. and whether they may cause tolerance or resistance of T cells to levels of sPD-1/sPD-L1 in MS patients and to determine whether can also be compared. Furthermore, it is necessary to assess the MS patients at different stages and following different treatments or polymerase chain reaction. The expression of PD-1/PD-L1 in non-autoimmune diseases can be detected using flow cytometry immune cells of MS patients is lower than that of patients with homeostasis in MS.

upregulation of PD-1/PD-L1 in tumor microenvironment (Haxhinasto et al., 2008; Patsoukis et al., 2012a). Zheng et al. (2019) found that the expression of miR-21 in patients with gastric cancer resection was decreased, which affected the differentiation of T cells by upregulating PD-1/PD-L1. Low miR-21 expression resulted in an imbalance of Th17/Treg cells (an increase in the number of Treg cells and a decrease in the number of Th17 cells). The upregulation of miR-21 increased the number of Th17 cells (Zheng et al., 2019). Many miRNAs are involved in the pathogenesis of MS. Previous data has confirmed a tight connection between miRNAs and PD-1/PD-L1, suggesting that miRNAs alter immune function by regulating the PD-1/PD-L1 axis (Ashrafzadeh et al., 2020). Taken together, miRNAs regulate the expression of PD-1/PD-L1 and may be used as therapeutic targets for MS.

CONCLUDING REMARKS AND FUTURE DIRECTIONS

The upregulation of PD-1/PD-L1 in tumor microenvironment leads to impaired immune cell function and premature apoptosis. Autoimmune diseases are caused by excessive immune responses, resulting in damage to normal tissues. The PD-1/PD-L1 signaling pathway may be dysregulated in MS [e.g., the dysregulated PD-1 axis in AIH (Aarslev et al., 2017)]. The loss of immune homeostasis leads to a robust immune response that cannot be controlled properly. The loss of immune homeostasis in MS may be related to genetic interactions, environmental factors, dietary factors, or other diseases. The PD-1 receptor needs to bind to its ligand in order to suppress the effector immune response. Therefore, two reasons may explain the dysregulation of the PD-1/PD-L1 signaling pathway. Firstly, the number of immune cells increases sharply, but the upregulation of PD-L1 is a slow process. Secondly, the expression PD-1 on cells may be impaired under the stimulation of cytokines or Ag receptors, leading to excessive immune responses. Future investigations should focus on whether the increase in the amount of PD-L1 and/or the upregulation of PD-1 on immune cells can restore immune homeostasis in MS.

In future studies, whether the expression of PD-1/PD-L1 in the immune cells of MS patients is lower than that of patients with non-autoimmune diseases can be detected using flow cytometry or polymerase chain reaction. The expression of PD-1/PD-L1 in MS patients at different stages and following different treatments can also be compared. Furthermore, it is necessary to assess the levels of sPD-1/sPD-L1 in MS patients and to determine whether they play a proinflammatory or anti-inflammatory role in MS and whether they may cause tolerance or resistance of T cells to the PD-1 pathway.

Whether the PD-1 pathway fails to exert an immunosuppressive effect in MS also warrants investigation. Attention should be paid to the selection of healthy subjects as the control group, since the PD-1/PD-L1 pathway is only activated when immune cells are activated. It may be more appropriate to compare MS patients at different stages. Immune cell extraction and in vitro cell culture may also be performed and genetic testing can be used to explore whether the mutation on PD-1/PD-L1 exists in MS. It is also worthy to explore whether the transcription and translation of the mutant gene, and the post-translational modification and the immune function of the synthetic PD-1/PD-L1 proteins are altered in MS. Moreover, transcriptomics, proteomics, and metabolomics can be used to assess functional changes of immune cells expressing PD-1/PD-L1 in MS patients.

Should future studies suggest that the PD-1 pathway is changed in MS, molecules that can alter the levels of PD-1/PD-L1 (such as sPD-L1) may be used to regulate the immunosuppressive function of the PD-1 pathway in MS. In addition, the downstream targets of the PD-1/PD-L1 pathway (such as SHP2 and PTEN agonists, PI3K/akt/mTOR inhibitors, etc.) may also be potential therapeutic targets for MS. However, drugs that inhibit the proliferation and differentiation of immunomodulatory immune cells may not be beneficial to the regeneration and recovery of myelin. Gene therapy may also be used to regulate the PD-1/PD-L1 pathway in immune cells. However, whether high PD-1/PD-L1 expression will increase carcinogenic risk should be investigated. The anti-PD-1 antibody has been found to induce autoimmune diseases in cancer treatment (Naidoo et al., 2016; Sibaud, 2018) and therefore might also exert toxic effects in MS patients.

AUTHOR CONTRIBUTIONS

HL drafted the manuscript. CZ, JH, and SL helped to edit the manuscript. TJ and JZ performed the critical revisions. All authors read and approved the final manuscript.

FUNDING

This work was supported by grants from the General Program of the National Natural Science Foundation of China (No. 81671177), Natural Science Foundation of Jilin Province Science and Technology Development Plan Project (20190201043JC), Key Research and Development Project of Social Development Division of Jilin Science and Technology Department (20200403109SF), Special Project for Health Professionals of Jilin Provincial Finance Department (JLSWSRCZX2020-0056), as well as the grants from the Swedish Research Council (No. 2015-03005), and grants from The First Hospital, Jilin University of China.

ACKNOWLEDGMENTS

We thank Medjaden Inc. for the scientific editing of this manuscript.
REFERENCES

Aarslev, K., Dige, A., Greisen, S. R., Kreutzfeldt, M., Jessen, N., Vilstrup, H., et al. (2017). Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scand. J. Gastroenterol. 52, 93–99. doi: 10.1080/03004571.2016.1233576

Abu Hejleh, T., Furqan, M., Ballas, Z., and Clamon, G. (2019). The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Crit. Rev. Oncol. Hematol. 143, 148–152. doi: 10.1016/j.critrevonc.2019.08.009

Allen, C. D., Okada, T., Tang, H. L., and Cyster, J. G. (2007). Imaging of germinal center selection events during affinity maturation. Science 315, 528–531. doi: 10.1126/science.1136736

Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Allen, C. D., Okada, T., Tang, H. L., and Cyster, J. G. (2007). Imaging of germinal Aarslev, K., Dige, A., Greisen, S. R., Kreutzfeldt, M., Jessen, N., Vilstrup, H., et al. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482–1490. doi: 10.1002/eji.200425405

Austin, J. W., Lu, P., Majumder, P., Ahmed, R., and Boss, J. M. (2014). STAT3, cytokines compromise programmed cell death-1 (PD-1)-mediated T cell regulation in patients with idiopathic inflammatory myopathies. J. Immunol. 192, 4876–4886. doi: 10.4049/jimmunol.1302730

Bao, L., Yan, Y., Xu, C., Ji, W., Shen, S., Xu, G., et al. (2013). MicroRNA-ligand 13 plays a role in experimental autoimmune encephalomyelitis. J. Immunol. 190, 7496–7508. doi: 10.4049/jimmunol.1300612

Bartlett, B., Littman, D. R., and Flavell, R. A. (2007). The role of the Tc17 subset in autoimmune disease. Nat. Immunol. 8, 751–759. doi: 10.1038/ni1379

Bell, A. G., and Kipnis, J. (2011). Regulatory T cells suppress Th17 responses in multiple sclerosis, but not in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 233, 31–36. doi: 10.1016/j.jneuroim.2011.04.001

Billich, A., Baumrucker, T., Heining, P., Schmucker, R., Francis, G., et al. (2010). Fingolimod (FTY720): development and an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897. doi: 10.1038/nrd3248

Brown, J. A., Dorfman, D. M., Ma, F. R., Sullivan, E. L., Munoz, O., Wood, C. R., et al. (2003). Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266. doi: 10.4049/jimmunol.170.3.1257

Carter, L. L., Leach, M. W., Azoitei, M. L., Cui, J., Pelker, J. W., Jussil, J., et al. (2007). PD-1/PD-L1 interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182, 124–134. doi: 10.1016/j.jneuroim.2006.10.006

Carter, N. A., Rosser, E. C., and Mauri, C. (2012). Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14:R32.

Celada, L. J., Kropski, J. A., Herazo-Maya, J. D., Luo, W., Creecy, A., and Abad, A. T. (2018). PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci. Transl. Med. 10:eaar8356. doi: 10.1126/scitranslmed.aar8356

Chavali, P. L., Funa, K., and Chavali, S. (2011). Cis-regulation of microRNA expression by scaffold/matrix-attachment regions. Nucleic Acids Res. 39, 6908–6918. doi: 10.1093/nar/gkx303

Chen, L. (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4, 336–347. doi: 10.1038/nri1349

Cheng, Y., Sun, L., Xie, Z., Fan, X., Cao, Q., Han, J., et al. (2017). Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. J. Neurosci. Res. 95, 1973–1983. doi: 10.1002/jnr.24023

Ciotti, J. R., and Cross, A. H. (2018). Disease-modifying treatment in progressive multiple sclerosis. Curr. Treat. Options Neurol. 20:12.

Claes, N., Dhaeze, T., Fraussen, J., Broux, B., Van Wijmeersch, B., Stinissen, P., et al. (2014). Proportional changes of B and T cell subtypes by fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One 9:e111115. doi: 10.1371/journal.pone.0111115

Cohen, J. A., Barkhoff, F., Conu, G., Hartung, H. P., Khatri, B. O., Montalban, X., et al. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415.

Curran, C. S., and Sharon, E. (2017). PD-1 immunobiochemistry in autoimmune hepatitis and hepatocellular carcinoma. Semin. Oncol. 44, 428–432. doi: 10.1053/j.seminoncol.2017.12.001

Danikowski, K. M., Jayaraman, S., and Prabhakar, B. S. (2017). Regulatory T cells in multiple sclerosis and myasthenia gravis. J. Neuroinflammation 14:117.

Ding, Y., Han, R., Jiang, W., Xiao, J., Liu, H., Chen, X., et al. (2016). Programmed death Ligand 1 Plays a Neuroprotective role in experimental autoimmune neuritis by controlling peripheral nervous system inflammation of rats. J. Immunol. 197, 3831–3840. doi: 10.4049/jimmunol.1601083

Dobson, R., and Giovanonni, G. (2019). Multiple sclerosis - a review. Eur. J. Neurol. 26, 27–40.

Dong, H., Strome, S. E., Matteson, E. L., Moder, K. G., Flies, D. B., Zhu, G., et al. (2003). Costimulating abberant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J. Clin. Invest. 111, 363–370. doi: 10.1172/jci160183

Dulos, J., Carven, G. J., van Boxtel, S. J., Evers, S., Driessen-Engels, L. J., Hafezi, H., Ahmadi, M., Mozafarpoor, S., et al. (2018). PD-1 up-regulation on CD4(+) T cells abrogates in the absence of B cells. J. Exp. Med. 215, 1365–1379. doi: 10.1084/jem.20172475

Eienen, E., Heinz, M., Sznitowska, I., Geisel, M., Nadler, J., and Tandy, T. (2010). Fingolimod (FTY720) abrogates in the absence of B cells. Eur. J. Immunol. 41, 1165–1175. doi: 10.1002/eji.201040992

Eisenhut, J. H., Helou, Y. A., Chopra, G., Weiss, A., and Bluestone, J. A. (2016). CD28 costimulation: from mechanism to therapy. Immunology 44, 973–988. doi: 10.1080/08820139.2016.1163640

Fathi, F., Sadeghi, E., Lotfi, N., Hafezi, H., Ahmadi, M., Mozafarpoor, S., et al. (2020). Effects of the programmed cell death 1 (PDCD1) polymorphisms in susceptibility to systemic lupus erythematosus. Int. J. Immunogenet. 47, 57–64. doi: 10.1111/iji.12456

Feng, X., Bao, R., Li, L., Deisenhammer, F., Arisona, B. G. W., and Reder, A. T. (2010). Interferon-β corrects massive gene dysregulation in multiple sclerosis: short-term and long-term effects on immune regulation and neuroprotection. EbioMedicine 49, 269–283. doi: 10.1016/j.ebiom.2019.09.059

Ferrajoli, A., Shanafelt, T. D., Ivan, C., Shimizu, M., Rabe, K. G., Nouraei, N., et al. (2013). Prognostic value of miR-155 in individuals with monoclonal B-cell
lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 122, 1891–1899.

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., et al. (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029. doi: 10.1084/jem.20090043

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2010). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034. doi: 10.1084/jem.2009.1027

Garcia, J., Hendel-Chavez, H., de-Goer, M. G., l'Honneur, A. S., Dubessy, A. L., Taoufik, Y., et al. (2020). Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T cells exhaustion. Mult. Scler. 26, 640–644. doi: 10.1177/1352458520942201

Garcia, K. C., Adams, J. J., Feng, D., and Ely, L. K. (2009). The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat. Immunol. 10, 143–147. doi: 10.1038/nli.219

Glattigny, S., and Betelli, E. (2018). Experimental autoimmune encephalomyelitis (EAE) as animal models of multiple sclerosis (MS). Cold Spring Harb. Perspect. Med. 2018a028977. doi: 10.1101/cshperspect.a028977

Gonzalez, L. C., Loyet, K. M., Calemire-Fenaux, J., Chauhan, V., Wranik, B., Ouyang, W., et al. (2005). A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl. Acad. Sci. U. S. A. 102, 1116–1121. doi: 10.1073/pnas.0409071102

Good-Jacobson, K. L., Song, E., Anderson, S., Sharpe, A. H., and Shlomchik, M. J. (2012). CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. J. Immunol. 188, 4217–4225. doi: 10.4049/jimmunol.1102885

Good-Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M., and Shlomchik, M. J. (2010). PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 11, 535–542. doi: 10.1038/nli.1877

Groh, J., Friedman, H. C., Orel, N., Ip, C. W., Fischer, S., Spahn, L., et al. (2016). Pathogenic inflammation in the CNS of mice carrying human PLP1 mutations. Hum. Mutat. 25, 4686–4702.

Groh, J., Hörner, M., and Martini, R. (2018). Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations. J. Neuroinflammation 15:194.

Hadj, T., Gillespie, S., Espinoza, H., Prince, J., Gronbaek, H., Chandrakasan, S., et al. (2020). Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. Autoimmunity 53, 253–260. doi: 10.1080/08966072.2020.1755964

Haribhai, D., Chatila, T. A., and Williams, C. B. (2016). Immunotherapy with iTreg cells in a murine model of inflammatory bowel disease. Circulating precursor CCR7(lo)PD-1(hi) CXCR5? CD4? T cells indicate Tfh cell and nTreg cells in a murine model of inflammatory bowel disease. J. Exp. Med. 203, 883–895. doi: 10.1084/jem.20051776

Hirokawa, K., and Martini, R. (2018). Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci. Transl. Med. 11:aao5563.

Kong, E. K., Prokunina-Olsson, L., Wong, W. H., Lau, C. S., Chan, T. M., Alarcón-Riquelme, M., et al. (2005). A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 52, 1058–1062. doi: 10.1002/art.20966

Kornberg, M. D., and Bhargava, P. (2018). Dimethyl fumarate targets GAPDH and acetyl coA carboxylase to modulate the tumor microenvironment. Science 359, 1391–1395. doi: 10.1126/science.aao7806

Kuchroo, V. K., et al. (2009). PD-L1 regulates the development, germinal center B cell survival, and plasma cell generation. J. Immunol. 183, 1280–1290. doi: 10.4049/jimmunol.1102885

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., et al. (2012). PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation and function of induced regulatory T cells. EMBO J. 21, 965–977. doi: 10.1002/embj.201100276
Lee, G. R. (2018). The balance of Th17 versus Treg cells in autoimmunity. Immunol. Lett. 197:30. doi: 10.1016/j.imlet.2018.06.005

Leonard, W. J., and Lin, J. X. (2000). Cytokine receptor signaling pathways. J. Allergy Clin. Immunol. 105, 877–888. doi: 10.1067/mcl.2000.106899

Li, J., Iie, H. B., Lei, Y., Gildener-Leapman, N., Trivedi, S., Green, T., et al. (2015). PD-1 deficiency inhibits Tc1/Tc1 phenotype responses and the activation of T cells in the tumor microenvironment. Cancer Res. 75, 508–518. doi: 10.1158/0008-5472.can-14-1215

Littman, D. R., and Rudensky, A. Y. (2010). Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 854–858. doi: 10.1016/j.cell.2010.02.021

Liu, C., Jiang, J., Gao, L., Wang, X., Hu, X., Wu, M., et al. (2015). Soluble PD-L1 inhibits Th1 cell activation by distinct mechanisms. Mol. Cell. Biol. 35, 1053–1064. doi: 10.1128/mcb.01409-14

Liu, X., Hu, L. H., Li, Y. R., Chen, F. H., Ning, Y., and Yao, Q. F. (2011). Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatol. Int. 31, 209–213. doi: 10.1007/s00296-009-0926-4

Ma, J., Zheng, B., Goswami, S., Meng, L., Zhang, D., Cao, C., et al. (2019). PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J. Immunother. Cancer 7:331.

Mahoney, K. M., and Shukla, S. A. (2019). A secreted PD-L1 splice variant that covalently dimersizes and mediates immunosuppression. Cancer Immunol. Immunother. 68, 421–432. doi: 10.1007/s00262-018-2282-1

Malumbres, M., and Barbacid, M. (2003). RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459–465. doi: 10.1038/nrc1097

Mansoor, S. R., Ghasemi-Kasman, M., and Youvarpour-Bali, H. (2020). The role of microRNAs in multiple sclerosis. Int. Rev. Immunol. 7, 56–59. doi: 10.1080/08830185.2020.1701019

Mao-Draayer, Y., Sarazin, J., Fox, D., and Schiopu, E. (2017). The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. Eur. J. Immunol. 38, 1734–1744. doi: 10.1002/eji.200738071

Papenfuss, T. L., Powell, N. D., McClain, M. A., Bedar, A., Singh, A., Giannop, I. E., et al. (2011). Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J. Immunol. 186, 3346–3355. doi: 10.4049/jimmunol.1001322

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunerstein, S., Kobayashi, S. V., et al. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553. doi: 10.1128/mcb.25.21.9543-9553.2005

Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., and Boussiotis, V. A. (2012a). Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 5:xra46. doi: 10.1126/scisignal.2002796

Patsoukis, N., Sari, D., and Boussiotis, V. A. (2012b). PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdca5A. Cell Cycle 11, 4305–4309. doi: 10.4161/cc.22135

Pawlak-Adamśka, E., Nowak, O., Karabin, L., Pokryszko-Dragan, A., Partyka, A., Tomkiewicz, A., et al. (2017). PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. J. Neuroimmunol. 305, 115–127. doi: 10.1016/j.jneuroim.2017.02.006

Peng, C., Hu, Q., Yang, F., Zhang, H., Li, L., and Huang, C. (2019). BCL6-mediated silencing of pd-1 ligands in germinal center b cells maintains follicular t cell population. J. Immunol. 202, 704–713. doi: 10.4049/jimmunol.1800876

Pentcheva-Hoang, T., Chen, L., Pardoll, D. M., and Allison, J. P. (2007). Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc. Natl. Acad. Sci. U. S. A. 104, 17765–17770. doi: 10.1073/pnas.0708767104

Piket, E., Zheleznyakova, G. V., Kular, L. and Jagodic, M. (2019). Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: a comprehensive overview. J. Autoimmun. 101, 17–25. doi: 10.1016/j.jaut.2019.04.002

Porta, C., Paglino, C., and Mosca, A. (2014). Targeting PI3K/Akt/mTOR signaling in cancer. Front. Oncol. 4:646.

Prokunina, L., Castillo-Lejóz, C., Oberg, F., Gunnarsson, I., Berg, L., Magnusson, V., et al. (2002). A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666–669.

Qian, C., Guo, H., Chen, X., Shi, A., Li, S., Wang, X., et al. (2018). Association of PD-1 and PD-L1 genetic polymorphisms with Type 1 diabetes susceptibility. J. Diabetes Res. 2018:1614683.

Quinn, J. L., and Astell, R. C. (2018). Emerging role of follicular T helper cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Int. J. Mol. Sci. 19:3233. doi: 10.3390/ijms19032333

Rae-Grant, A., Day, G. S., Marrie, R. A., Rabinstein, A., Cree, B. A. C., Gronseth, G. S., et al. (2018). Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology 90, 777–788.

Rekik, R., Belhadj Hmida, N., Ben Hmid, A., Zamali, I., Kammoun, N., and Ben Ahmed, M. (2015). PD-1 induction through TCR activation is partially regulated by endogenous TGF-β. Cell Mol. Immunol. 12, 648–649. doi: 10.1038/ cmi.2014.104

Renrick, A. N., Thounaojam, M. C., de Aquino, M. T. P., Chaudhuri, E., Pandhare, J., Dash, C., et al. (2021). Bortezomib sustains T Cell function by inducing PD-1 and PD-L1 genetic polymorphisms with Type 1 diabetes susceptibility.
Serriari, N. E., Gondois-Rey, F., Guillaume, Y., Remmerswaal, E. B., Pastor, S., Schmitt, N. (2015). Role of T follicular helper cells in multiple sclerosis. Frontiers in Cellular Neuroscience | www.frontiersin.org

Sharpe, A. H., Wherry, E. J., Ahmed, R., and Freeman, G. J. (2007). The function

Seifert, H. A., Gerstner, G., Kent, G., Vandenbark, A. A., and Offner, H. (2019).

Li et al. Targeting PD-1 for MS

Sharpe, A. H., Li, Z., Liu, Z., Sun, G., Mor, G., and Liao, A. (2016). The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. Sci. Rep. 6:27683.

Toellner, K. M., Gulbranson-Judge, A., Taylor, D. R., Sze, D. M., and MacLennan, I. C. (1996). Immunoglobulin switch transition script production in vivo related to the site and time of antigen-specific B cell activation. J. Exp. Med. 183, 2303–2312. doi: 10.1084/jem.183.5.2303

Trabattoni, D., Saresella, M., Pacci, M., Marventano, I., Mendoza, L., Rovaris, M., et al. (2009). Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J. Immunol. 183, 4984–4993. doi: 10.4049/jimmunol.0901038

Tüfekci, K. U., Oner, M. G., Genc, S., and Genc, K. (2010). MicroRNAs and multiple sclerosis. Autoimmune Dis. 2011:807426.

Vajavaara, H., and Mortensen, J. B. (2021). Soluble PD-1 but not pd-1 levels predict poor outcome in patients with high-risk diffuse large b-cell lymphoma. Cancers 13:398. doi: 10.3390/cancers13030398

Wagner, C. A., Roqué, P. J., and Goverman, J. M. (2020). Pathogenic T cell cytokines in multiple sclerosis. J. Exp. Med. 217:e20190460.

Waisman, A., Hauptmann, J., and Regen, T. (2015). The role of IL-17 in CNS diseases. Acta Neuropathol. 129, 623–637. doi: 10.1007/s00401-015-1402-7

Wan, B., Nie, H., Liu, A., Feng, G., He, D., Xu, R., et al. (2006). Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177, 8844–8850. doi: 10.4049/jimmunol.177.12.8844

Wang, C., Dehghani, B., Li, Y., Kaler, L. J., Proctor, T., Vandenbark, A. A., et al. (2009). Membrane estrogen receptor regulates experimental autoimmunity encephalomyelitis through up-regulation of programmed death 1. J. Immunol. 182, 3294–3303. doi: 10.4049/jimmunol.0803205

Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., and Honjo, T. (2005). Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 102, 11823–11828. doi: 10.1073/pnas.050497102

Warshawsky, I., Rudick, R. A., Staugaitis, S. M., and Natowicz, M. R. (2005). Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. Ann. Neurol. 58, 470–473. doi: 10.1002/ana.20601

Wei, L., Laurence, A., and O'Shea, J. J. (2008). New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin. Cell Dev. Biol. 19, 394–400. doi: 10.1016/j.semcdb.2008.07.011

Weng, W., Xiang, J., Li, H., Xie, Y.,胬, S., et al. (2017). RNA-seq analysis identifies a PD-1/p53 signaling axis in multiple sclerosis. Cell. Mol. Immunol. 14, 166–176.

Wu, D., Liu, Y., Pang, N., Sun, M., Wang, X., Haridja, Y., et al. (2019). PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and Treg/Th17 cells subtypes in immune thrombocytopenic purpura patients. Medicine 98:e17608. doi: 10.1097/md.0000000000017608

Wu, H., Miao, M., Zhang, G., Hu, Y., Ming, Z., and Zhang, X. (2009). Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. Immunol. Invest. 38, 408–421. doi: 10.1080/0882030902912332
Zhang, J., and Braun, M. Y. (2014). PD-1 deletion restores susceptibility to
secondary progressive multiple sclerosis. *JCI Insight* 5:e134251.

Xia, Y., Jeffrey Medeiros, L., and Young, K. H. (2016). Signaling pathway and
dysregulation of PD1 and its ligands in lymphoid malignancies. *Biochim. Biophys. Acta* 1865, 58–71. doi: 10.1016/j.bbacli.2015.09.002

Xing, K., Gu, B., Zhang, P., and Wu, X. (2015). Dexamethasone enhances
programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. *BMC Immunol.* 16:39.

Yan, X., Gu, Y., Wang, C., Sun, S., Wang, X., Tian, J., et al. (2019). Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis. *Clin. Immunol.* 207, 68–78. doi: 10.1016/j.clim.2019.07.011

Yang, M. G., Sun, L., Han, J., Zheng, C., Liang, H., Zhu, J., et al. (2019). Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis. *Mol. Brain* 12:115.

Yee, D., Shah, K. M., Coles, M. C., Sharp, T. V., and Lagos, D. (2017). MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. *J. Biol. Chem.* 292, 20683–20693. doi: 10.1074/jbc.m117.809053

Yeh, T. H., and Lin, J. Y. (2020). Acorus gramineusand and euodia ruticarpa
steam distilled essential oils exert anti-inflammatory effects through decreasing Th1/Th2 and Pro-/Anti-Inflammatory cytokine secretion ratios in vitro. *Biomolecules* 10:338. doi: 10.3390/biom10020338

Zamani, M. R., Aslani, S., Salmaninejad, A., Javan, M. R., and Rezaei, N. (2016). PD-L and autoimmunity: a growing relationship. *Cell Immunol.* 310, 27–41. doi: 10.1016/j.cellimm.2016.09.009

Zare-Shahabadi, A., Renaudineau, Y., and Rezaei, N. (2013). MicroRNAs and
multiple sclerosis: from physiopathology toward therapy. *Expert Opin. Ther. Targets* 17, 1497–1507. doi: 10.1517/14728222.2013.838219

Zhang, J., and Braun, M. Y. (2014). PD-1 deletion restores susceptibility to
experimental autoimmune encephalomyelitis in miR-155-deficient mice. *Int. Immunol.* 26, 407–415. doi: 10.1093/intimm/dxu045

Zhang, Y., Liu, Z., Tian, M., Hu, X., Wang, L., Ji, J., et al. (2018). The altered PD-1/PD-L1 pathway delivers the ‘one-two-punch’ effects to promote the Treg/Th17 imbalance in pre-eclampsia. *Cell Mol. Immunol.* 15, 710–723. doi: 10.1038/cmi.2017.70

Zhao, J., Pan, X., Xing, Y., Lu, M., Chen, Y., and Shi, M. (2015). [Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism]. *Zhonghua Yi Xue Za Zhi* 95, 449–452.

Zheng, X., Dong, L., Wang, K., Zou, H., Zhao, S., Wang, Y., et al. (2019). MiR-21 participates in the PD-1/PD-L1 pathway-mediated imbalance of Th17/Treg cells in patients after gastric cancer resection. *Ann. Surg. Oncol.* 26, 884–893. doi: 10.1245/s10434-018-07117-6

Zhou, J., Mahoney, K. M., Giobbie-Hurder, A., Zhao, F., Lee, S., Liao, X., et al. (2017). Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. *Cancer Immunol. Res.* 5, 480–492. doi: 10.1158/2326-6066.cir-16-0329

Zhu, B., Guleria, I., Khosroshahi, A., Chitnis, T., Imitola, J., Azuma, M., et al. (2006). Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. *J. Immunol.* 176, 3480–3489. doi: 10.4049/jimmunol.176.6.3480

Zilber, E., Martin, G. E., Willberg, C. B., Fox, J., Nwokolo, N., and Fidler, S. (2019). Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. *AIDS* 33, 1253–1256. doi: 10.1097/qad.0000000000002165

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Zheng, Han, Zhu, Liu and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.